This is our Difference
Nature
Oleanolic Acid is a triterpenoid widely found in plants, most notably olives, and is the heart of the plant’s defense mechanisms. Safely ingested for centuries, Oleanolic Acid has throughout history been believed to have healing properties. TTX has set out to reconstruct and modify Oleanolic Acid’s chemical structure to rapidly accelerate and exponentially strengthen its true natural power.
Science
Thirteen chemical steps. Years of commitment. It took thirteen chemical steps and years of commitment to constant improvement to formulate the synthetic scaffold that TTX drugs are platformed on. TTX Founder Dr. Michael B. Sporn has designed over 500 triterpenoid drugs, including Bardoxolone, now in clinical trials for the treatment of kidney disease. The company’s expanding pipeline is comprised of the latest and most powerful triterpenoids known to date.
Innovation
TTX drugs are designed to treat disease comprehensively. They target cellular networks and tumor micro-environments through novel mechanisms of action that reduce the inflammation and oxidative stress which accompany disease. They show additional promise by enhancing the ability of existing standards of care to overcome resistance. With fourteen compounds in development, TTX plans to aggressively test its pipeline and improve the lives of those who suffer from cancer and other chronic diseases.